SIGLEC10 and neoplasm: For the MC38, 4T1 and CT26 tumor models (Fig. 4a–c), intratumoral injection of OAd-null, OAd-SIRPα-Fc, OAd-Siglec10-Fc, or OAd-TIGIT-Fc in the corresponding model was significantly more potent than that of OAd-null regarding tumor growth inhibition (Fig. 4d–f) and survival prolongation (Fig. 4g–i), suggesting that SIRPα-Fc, Siglec10-Fc, and TIGIT-Fc were important contributors to the antitumor effect in addition to exerting direct oncolytic activity.